United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

takeda uk ltd - pioglitazone hydrochloride - tablet - 30mg

Israel - English - Ministry of Health

tzamal bio-pharma ltd - pioglitazone as hydrochloride - tablets - pioglitazone as hydrochloride 30 mg - pioglitazone - pioglitazone - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below: as monotherapy- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as dual oral therapy in combination with - metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination with- metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance .

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة العربية لصناعة الادوية المساهمة الخاصة - the arab pharmaceutical manufacturing psc - pioglitazone 30 mg - 30 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - pioglitazone hydrochloride, quantity: 33.06 mg (equivalent: pioglitazone, qty 30 mg) - tablet, uncoated - excipient ingredients: lactose monohydrate; carmellose calcium; magnesium stearate; hyprolose - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control: in combination with metformin or sulfonylurea; in combination with insulin. as triple therapy to improve glycaemic control: in combination with metformin and sulfonylurea.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - lansoprazole, quantity: 30 mg - tablet, orally disintegrating - excipient ingredients: iron oxide yellow; macrogol 8000; hypromellose; hyprolose; magnesium carbonate hydrate; citric acid; magnesium stearate; crospovidone; iron oxide red; triethyl citrate; microcrystalline cellulose; polysorbate 80; mannitol; aspartame; glyceryl monostearate; titanium dioxide; purified talc; lactose monohydrate; flavour; purified water; methacrylic acid copolymer; sodium lauryl sulfate; polyacrylate dispersion (30 per cent) - adults 1. healing and long-term management of reflux oesophagitis. 2. healing and long-term management for patients with duodenal ulcer. 3. healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 4. lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists. 5. eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials). 6. relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia. paediatric patients 6 to 17 years of age. 1. treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis. 2. healing of erosive oesophagitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: stearic acid; hypromellose; colloidal anhydrous silica - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose. during controlled clinical trials in patients with type ii diabetes, gliclazide mr 30 mg tablets, taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: hypromellose; stearic acid; colloidal anhydrous silica - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose. during controlled clinical trials in patients with type ii diabetes, gliclazide mr 30 mg tablets, taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - mirtazapine, quantity: 30 mg - tablet, film coated - excipient ingredients: macrogol 8000; hyprolose; iron oxide yellow; colloidal anhydrous silica; iron oxide red; iron oxide black; hypromellose; magnesium stearate; titanium dioxide; maize starch; lactose monohydrate - treatment of major depression.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - mirtazapine, quantity: 30 mg - tablet, film coated - excipient ingredients: hyprolose; maize starch; magnesium stearate; lactose monohydrate; colloidal anhydrous silica; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; iron oxide black - treatment of major depression including relapse prevention.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - mirtazapine, quantity: 30 mg - tablet, film coated - excipient ingredients: macrogol 8000; hyprolose; iron oxide yellow; colloidal anhydrous silica; iron oxide red; iron oxide black; hypromellose; magnesium stearate; titanium dioxide; maize starch; lactose monohydrate - treatment of major depression.